新諾威(300765.SZ):擬對河北果維康和中諾泰州兩大生產基地進行整合
格隆匯 8 月 3日丨新諾威(300765.SZ)公佈,公司於2020年7月31日召開了第五屆董事會第三次會議,審議通過了《關於全資子公司擬停產搬遷的議案》。
目前公司維生素類保健食品主要由位於河北省石家莊市的河北中諾果維康保健品有限公司(“河北果維康”)及位於江蘇省泰州市的石藥集團中諾藥業(泰州)有限公司(“中諾泰州”)生產,中諾泰州的生產基地生產設施先進,於2017年建成投產後,產能不斷提升,擁有較高的研發和生產能力。為提升生產、經營管理效率,公司擬對河北果維康和中諾泰州兩大生產基地進行整合,河北果維康擬停產並將相關生產設施有序搬遷至中諾泰州。
此次河北果維康的停產搬遷系公司整合保健食品生產資源、提升管理效率的舉措,符合公司戰略佈局與未來業務規劃,不會對公司的生產經營造成不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.